Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMKLR1 | Q99788 | 3/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.38 |
| ▸ | FABP3 | P05413 | 3/20 | 0.38 |
| ▸ | FABP4 | P15090 | 3/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.37 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.35 |
| ▸ | MARS1 | P56192 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 2/20 | 0.35 |
| ▸ | CNR2 | P34972 | 2/20 | 0.35 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.35 |
| ▸ | CCKAR | P32238 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1131325 | 1.00 | CMKLR1 (0.40) | CMKLR1PTGS2FFAR4FFAR1FABP3 | |
| SCHEMBL1131312 | 0.93 | CMKLR1 (0.38) | CMKLR1PTGS2FFAR4FFAR1FABP3 | |
| SCHEMBL1131311 | 0.93 | CMKLR1 (0.38) | CMKLR1PTGS2FFAR4FFAR1FABP3 | |
| SCHEMBL1131843 | 0.88 | CMKLR1 (0.40) | CMKLR1PTGS2FFAR4FFAR1FABP3 | |
| SCHEMBL1131841 | 0.88 | CMKLR1 (0.40) | CMKLR1PTGS2FFAR4FFAR1FABP3 | |
| SCHEMBL1131371 | 0.85 | FAAH (0.37) | CMKLR1PTGS2FFAR4FFAR1FABP3 | |
| SCHEMBL1131367 | 0.85 | FAAH (0.37) | CMKLR1PTGS2FFAR4FFAR1FABP3 | |
| SCHEMBL1131301 | 0.84 | FFAR1 (0.39) | CMKLR1FFAR4FFAR1S1PR1PTGER4 | |
| SCHEMBL1132058 | 0.84 | FFAR4 (0.38) | PTGS2FFAR4FFAR1MARS1CNR1 | |
| SCHEMBL1132057 | 0.84 | FFAR4 (0.38) | PTGS2FFAR4FFAR1MARS1CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663105-B1 | CYCLOALKYL HETEROCYCLES FOR TREATING HEPATITIS C VIRUS | BRISTOL MYERS SQUIBB CO (US) | 2011-02-16 | — | — | EP | claimed |
| EP-1663105-A4 | CYCLOALKYL HETEROCYCLES FOR TREATING HEPATITIS C VIRUS | BRISTOL MYERS SQUIBB CO (US) | 2009-04-15 | — | — | EP | claimed |
| JP-2007505114-A | — | — | 2007-03-08 | — | — | JP | claimed |
| US-7112601-B2 | Cycloalkyl heterocycles for treating hepatitis C virus | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-09-26 | — | — | US | claimed |
| EP-1663105-A2 | CYCLOALKYL HETEROCYCLES FOR TREATING HEPATITIS C VIRUS | Bristol-Myers Squibb Company (US) | 2006-06-07 | — | — | EP | claimed |
| WO-2005034850-A2 | CYCLOALKYL HETEROCYCLES FOR TREATING HEPATITIS C VIRUS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-04-21 | — | — | WO | claimed |
| US-20050075376-A1 | Cycloalkyl heterocycles for treating Hepatitis C virus | BRISTOL-MYERS SQUIBB COMPANY | 2005-04-07 | — | — | US | claimed |
| EP-1663105-B1 | CYCLOALKYL HETEROCYCLES FOR TREATING HEPATITIS C VIRUS | BRISTOL MYERS SQUIBB CO (US) | 2011-02-16 | — | — | EP | disclosed |
| EP-1663105-A4 | CYCLOALKYL HETEROCYCLES FOR TREATING HEPATITIS C VIRUS | BRISTOL MYERS SQUIBB CO (US) | 2009-04-15 | — | — | EP | disclosed |
| US-7112601-B2 | Cycloalkyl heterocycles for treating hepatitis C virus | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-09-26 | — | — | US | disclosed |
| EP-1663105-A2 | CYCLOALKYL HETEROCYCLES FOR TREATING HEPATITIS C VIRUS | Bristol-Myers Squibb Company (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005034850-A2 | CYCLOALKYL HETEROCYCLES FOR TREATING HEPATITIS C VIRUS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-04-21 | — | — | WO | disclosed |
| US-20050075376-A1 | Cycloalkyl heterocycles for treating Hepatitis C virus | BRISTOL-MYERS SQUIBB COMPANY | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075376-A1 | Cycloalkyl heterocycles for treating Hepatitis C virus | HCCS, NSUN2, HAVCR2 | CMKLR1 4064/4885PTGS2 1124/4885FFAR4 4141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.